The role of pathology in predicting immunotherapy response in urogenital tumors


ÖZLÜK M. Y.

Turk Onkoloji Dergisi, vol.35, no.4, pp.492-496, 2020 (ESCI) identifier identifier

  • Publication Type: Article / Article
  • Volume: 35 Issue: 4
  • Publication Date: 2020
  • Doi Number: 10.5505/tjo.2020.2328
  • Journal Name: Turk Onkoloji Dergisi
  • Journal Indexes: Emerging Sources Citation Index (ESCI), Scopus, Academic Search Premier, CINAHL, EMBASE, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.492-496
  • Keywords: Cancer, Genitourinary, Immunotherapy, Pathology, PD-L1
  • Istanbul University Affiliated: Yes

Abstract

© 2020, Istanbul Tip Fakultesi. All rights reserved.Immune checkpoint inhibitors (ICI) are recently introduced in the management of various cancers. There are three main immunotargets as follows: Cytotoxic T-lymphocyte antigen-4 (CTLA4), programmed death 1 (PD-1) and programmed death ligand-1 (PD-L1). These three targets are under investigation for therapeutic, predictive and prognostic purposes in genitourinary cancers. There is a need for predictive biomarkers of immunotherapy to optimize treatment, to limit side-effects and to reduce the costs of therapy. This review focuses on the role of pathologic applications in the selection of patients with genitourinary cancer who are potentially responsive to immunotherapy. PD-L1 expression by im-munohistochemistry, tumor mutation burden and microsatellite instability status are mainly discussed.